Pharmaceutical major, Lupin Ltd on 18 September announced that they have signed a non-exclusive patent licensing arrangement to bring the novel gastrointestinal medication Vonoprazan tablets to India. 

The medication will be available in two dosages, 10 mg and 20 mg, and it will be marketed under the Lupivon brand. As per Lupin, the Drug Controller General of India (DCGI) has authorised Vonoprazan for managing reflux esophagitis, duodenal ulcers, gastric ulcers, and as a component of the Helicobacter pylori treatment regimen.

As per the deal, Takeda has granted Lupin non-exclusive rights to commercialise Vonoprazan in India.

Rajeev Sibal, president of India Region Formulations at Lupin, said, “We are very pleased to bring Vonoprazan to the market as a novel treatment option for acid peptic disorders. This move strengthens our gastroenterology portfolio and aligns with our commitment to introducing innovative medicines to address the unmet needs of our patients.”

Earlier in July, the company had signed a licence and supply agreement with Huons Co. Ltd for the registration and marketing of Cyclosporine Ophthalmic Nanoemulsion, a 0.4mL single-use vial, in Mexico.

Tired of missing hot stocks? Unicorn Signals provides powerful tools like stock scans and more help you make informed trading decisions. Download now and take control of your portfolio!